Improved fermentation processes for NS0 cell lines expressing human antibodies and glutamine synthetase

被引:20
作者
Dempsey, J [1 ]
Ruddock, S [1 ]
Osborne, M [1 ]
Ridley, A [1 ]
Sturt, S [1 ]
Field, R [1 ]
机构
[1] Cambridge Antibody Technol, Melbourn SG8 6JJ, Cambs, England
关键词
D O I
10.1021/bp0256061
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
To meet the increasing requirement for therapeutic antibodies to conduct clinical trials, an enhanced culture medium and fed-batch process was developed for GS-NS0 cell lines. This process was shown to produce high concentrations of monoclonal antibodies for several cell lines expressing different antibodies. Cells were adapted to growth in a glutamine- and serum-free medium containing bovine serum albumin (BSA), cholesterol, and transferrin. A number of amino acids were found to be depleted during cell culture. The concentrations of these amino acids were increased, and further cell culture analyses were performed. This process of cell growth and analysis was repeated over multiple cycles until no depletion was detected. This resulted in an amino acid supplement that was shown to be generic and enhanced antibody productivity up to 5-fold for the three cell lines tested. Transferrin was replaced using tropolone, a lipophilic iron chelator and ferric ammonium citrate. Cell growth was equivalent to that in transferrin-containing medium over the wide ranges tested. A concentrated feed solution, based on the amino acid supplement and the components of the serum-and protein-free supplements, was formulated. Addition of this feed in response to metabolic requirements resulted in a harvest titer a further 2-fold higher than the enhanced culture medium. Harvest antibody titers of up to 600 mg/L were achieved for three cell lines expressing different antibodies, representing an increase of 10-fold over the starting concentrations.
引用
收藏
页码:175 / 178
页数:4
相关论文
共 16 条
[1]  
[Anonymous], 1994, ANIMAL CELL TECHNOLO
[2]   HIGH-LEVEL EXPRESSION OF A RECOMBINANT ANTIBODY FROM MYELOMA CELLS USING A GLUTAMINE-SYNTHETASE GENE AS AN AMPLIFIABLE SELECTABLE MARKER [J].
BEBBINGTON, CR ;
RENNER, G ;
THOMSON, S ;
KING, D ;
ABRAMS, D ;
YARRANTON, GT .
BIO-TECHNOLOGY, 1992, 10 (02) :169-175
[3]  
deZengotita VM, 2000, BIOTECHNOL BIOENG, V69, P566, DOI 10.1002/1097-0290(20000905)69:5<566::AID-BIT11>3.0.CO
[4]  
2-4
[5]   Feeding of nutrients delays apoptotic death in fed-batch cultures of recombinant NS0 myeloma cells [J].
DiStefano, DJ ;
Mark, GE ;
Robinson, DK .
BIOTECHNOLOGY LETTERS, 1996, 18 (09) :1067-1072
[6]   THE LOSS OF ANTIBODY PRODUCTIVITY IN CONTINUOUS CULTURE OF HYBRIDOMA CELLS [J].
FRAME, KK ;
HU, WS .
BIOTECHNOLOGY AND BIOENGINEERING, 1990, 35 (05) :469-476
[7]   EXPRESSION OF HUMAN ANTI-TETANUS TOXOID ANTIBODY IN TRANSFECTED MURINE MYELOMA CELLS [J].
GILLIES, SD ;
DORAI, H ;
WESOLOWSKI, J ;
MAJEAU, G ;
YOUNG, D ;
BOYD, J ;
GARDNER, J ;
JAMES, K .
BIO-TECHNOLOGY, 1989, 7 (08) :799-804
[8]   TRANSIENT RESPONSES OF HYBRIDOMA CELLS IN CONTINUOUS-CULTURE TO STEP CHANGES IN AMINO-ACID AND VITAMIN CONCENTRATIONS [J].
HILLER, GW ;
CLARK, DS ;
BLANCH, HW .
BIOTECHNOLOGY AND BIOENGINEERING, 1994, 44 (03) :303-321
[9]  
Jager V, 1988, Cytotechnology, V1, P319, DOI 10.1007/BF00365077
[10]   Development of a serum-free medium using computer-assisted factorial design and analysis [J].
Lao, MS ;
Schalla, C .
CYTOTECHNOLOGY, 1996, 22 (1-3) :25-31